

Rolf Wagner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2658146/publications.pdf>

Version: 2024-02-01

8
papers

417
citations

1478505

6
h-index

1588992

8
g-index

8
all docs

8
docs citations

8
times ranked

718
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of ABT-267, a Pan-Genotypic Inhibitor of HCV NS5A. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 2047-2057.	6.4	120
2	<i>In Vitro</i> Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	117
3	<i>In Vitro</i> Activity and Resistance Profile of Dasabuvir, a Nonnucleoside Hepatitis C Virus Polymerase Inhibitor. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1505-1511.	3.2	109
4	Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530). <i>Journal of Medicinal Chemistry</i> , 2018, 61, 4052-4066.	6.4	42
5	Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a trans-Stilbene Analog with Good Oral Bioavailability. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 1153-1163.	6.4	17
6	High potency improvements to weak aryl uracil HCV polymerase inhibitor leads. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 4367-4369.	2.2	6
7	Discovery of fluorobenzimidazole HCV NS5A inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 5462-5467.	2.2	5
8	HCV NS5A as an Antiviral Therapeutic Target: From Validation to the Discovery and Development of Ombitasvir and Pibrentasvir as Components of IFN-Sparing HCV Curative Treatments. <i>Topics in Medicinal Chemistry</i> , 2019, , 133-156.	0.8	1